Logo image of CPHI

CHINA PHARMA HOLDINGS INC (CPHI) Stock Fundamental Analysis

NYSEARCA:CPHI - NYSE Arca - US16941T3023 - Common Stock - Currency: USD

1.4966  -0.06 (-4.06%)

After market: 1.5 +0 (+0.23%)

Fundamental Rating

0

CPHI gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. CPHI may be in some trouble as it scores bad on both profitability and health. CPHI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CPHI has reported negative net income.
In the past year CPHI has reported a negative cash flow from operations.
CPHI had negative earnings in each of the past 5 years.
In the past 5 years CPHI always reported negative operating cash flow.
CPHI Yearly Net Income VS EBIT VS OCF VS FCFCPHI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -35.23%, CPHI is in line with its industry, outperforming 47.72% of the companies in the same industry.
CPHI has a Return On Equity (-72.67%) which is in line with its industry peers.
Industry RankSector Rank
ROA -35.23%
ROE -72.67%
ROIC N/A
ROA(3y)-18.68%
ROA(5y)-32.54%
ROE(3y)-63.46%
ROE(5y)-90.06%
ROIC(3y)N/A
ROIC(5y)N/A
CPHI Yearly ROA, ROE, ROICCPHI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CPHI Yearly Profit, Operating, Gross MarginsCPHI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CPHI has been increased compared to 1 year ago.
The number of shares outstanding for CPHI has been increased compared to 5 years ago.
CPHI has a worse debt/assets ratio than last year.
CPHI Yearly Shares OutstandingCPHI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CPHI Yearly Total Debt VS Total AssetsCPHI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.03, we must say that CPHI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CPHI (-1.03) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.61 indicates that CPHI is somewhat dependend on debt financing.
The Debt to Equity ratio of CPHI (0.61) is worse than 64.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z -1.03
ROIC/WACCN/A
WACC8.02%
CPHI Yearly LT Debt VS Equity VS FCFCPHI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.79 indicates that CPHI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.79, CPHI is doing worse than 88.83% of the companies in the same industry.
A Quick Ratio of 0.26 indicates that CPHI may have some problems paying its short term obligations.
The Quick ratio of CPHI (0.26) is worse than 92.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.26
CPHI Yearly Current Assets VS Current LiabilitesCPHI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.83% over the past year.
CPHI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.74%.
The Revenue for CPHI have been decreasing by -10.68% on average. This is quite bad
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.72%
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y-13.59%
Revenue growth 5Y-10.68%
Sales Q2Q%-38.98%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPHI Yearly Revenue VS EstimatesCPHI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CPHI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CPHI Price Earnings VS Forward Price EarningsCPHI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CPHI Per share dataCPHI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CPHI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA PHARMA HOLDINGS INC

NYSEARCA:CPHI (4/17/2025, 8:10:42 PM)

After market: 1.5 +0 (+0.23%)

1.4966

-0.06 (-4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-25 2022-11-25/amc
Earnings (Next)N/A N/A
Inst Owners0.9%
Inst Owner Change0%
Ins Owners47.86%
Ins Owner Change0%
Market Cap4.88M
Analysts0
Price TargetN/A
Short Float %4.99%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.8
P/FCF N/A
P/OCF N/A
P/B 7.48
P/tB 22.54
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.17
BVpS0.2
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.23%
ROE -72.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.68%
ROA(5y)-32.54%
ROE(3y)-63.46%
ROE(5y)-90.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.83%
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.26
Altman-Z -1.03
F-Score1
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)9.83%
Cap/Depr(5y)13.3%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y-13.59%
Revenue growth 5Y-10.68%
Sales Q2Q%-38.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-67.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.94%
OCF growth 3YN/A
OCF growth 5YN/A